SPARK THERAPEUTICS, INC. Patent Applications Rejected
11 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2023-07-26: Application 18262959; Invention Compositions and Methods for Treating Hereditary Angioedema; Applicant Spark Therapeutics, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2023-07-13: Application 18261285; Invention Compositions and Methods for Treating Fabry Disease; Applicant Spark Therapeutics, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2022-07-29: Application 17816367; Invention Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease; Applicant SPARK THERAPEUTICS, INC.; Status Abandoned -- Failure to Respond to an Office Action.
- 2022-03-23: Application 15733246; Invention ADENO-ASSOCIATED VIRUS (AAV) VECTOR LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF USE; Applicant SPARK THERAPEUTICS, INC.; Status Abandoned -- Failure to Respond to an Office Action.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2023-07-26 | 18262959 | Compositions and Methods for Treating Hereditary Angioedema | Spark Therapeutics, Inc. | Abandoned -- Failure to Respond to an Office Action | US20240110201A1 | Christopher Riling Francis Pankowicz Sean Armour William John Quinn III Michael Preston Stephen Ioele Daniel Cohen Zhenwei Kelvin See | United States United States United States United States United States United States United States United States | TINSLEY, BRENDAN THOMAS |
| 2023-07-13 | 18261285 | Compositions and Methods for Treating Fabry Disease | Spark Therapeutics, Inc. | Abandoned -- Failure to Respond to an Office Action | US20240301380A1 | Sean Armour Daniel Cohen Christopher Riling | United States United States United States | NOAKES, SUZANNE MARIE |
| 2022-07-29 | 17816367 | Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20220387560A1 | George Buchlis Xavier Anguela Katherine A. High | United States Spain United States | NOBLE, MARCIA STEPHENS |
| 2022-03-23 | 15733246 | ADENO-ASSOCIATED VIRUS (AAV) VECTOR LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF USE | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20210371877A1 | Andrew William SHAW Xavier ANGUELA | United States United States | ABBOTT, KODYE LEE |
| 2021-07-29 | 17310378 | AAV VECTOR TREATMENT METHODS FOR LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS TYPE 2 | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20220184188A1 | David William ANDERSON Maryann TOTO Sue E.I. DASEN | United States United States United States | SULLIVAN, STEPHANIE LAUREN |
| 2021-04-07 | 17224367 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | SPARK THERAPEUTICS, INC. UNIVERSITÉ DE PARIS SORBONNE UNIVERSITÉ GENETHON INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) | Abandoned -- Failure to Respond to an Office Action | US20210246469A1 | Sébastien LACROIX-DESMAZES Federico MINGOZZI Jordan DIMITROV Christian LEBORGNE Sean ARMOUR | France United States France France United States | NICOL, ALEXANDER W |
| 2020-10-27 | 17050911 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | SPARK THERAPEUTICS, INC. UNIVERSITÉ DE PARIS SORBONNE UNIVERSITÉ GENETHON INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) | Abandoned -- Incomplete Application (Pre-examination) | US20210228738A1 | Sébastien LACROIX-DESMAZES Federico MINGOZZI Jordan DIMITROV Christian LEBORGNE Sean ARMOUR | France United States France France United States | |
| 2020-01-31 | 16635957 | FACTOR VIII (FVIII) GENE THERAPY METHODS | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20200237930A1 | Xavier ANGUELA | United States | SHIN, DANA H |
| 2018-10-10 | 16156649 | Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20190038724A1 | George Buchlis Xavier Anguela Katherine A. High | United States United States United States | NOBLE, MARCIA STEPHENS |
| 2018-04-27 | 15772025 | CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS | SPARK THERAPEUTICS, INC. | Abandoned -- Failure to Respond to an Office Action | US20180312571A1 | Xavier ANGUELA Sam Hsien-i SHEN | United States United States | MOLOYE, TITILAYO |
| 2016-04-29 | 15143272 | Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | Spark Therapeutics, Inc. | Abandoned -- Failure to Respond to an Office Action | US20160346359A1 | George Buchlis Xavier Anguela Katherine A. High | United States United States United States | NOBLE, MARCIA STEPHENS |